ATQP Stock Chart & Stats
€39.20
-€0.40(-1.01%)
At close: 4:00 PM EDT
€39.20
-€0.40(-1.01%)
Day’s Range― - ―
52-Week Range€25.40 - €41.60
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€1.87B
Enterprise Value€2.26K
Total Cash (Recent Filing)€162.46M
Total Debt (Recent Filing)€92.54M
Price to Earnings (P/E)85.8
Beta0.58
Next Earnings
Nov 11, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.48
Shares Outstanding51,206,615
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.91
Price to Book (P/B)5.14
Price to Sales (P/S)6.59
P/FCF Ratio73.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€53.76Price Target Upside37.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.47
Revenue Forecast (FY)€287.63M
Bulls Say, Bears Say
Bulls Say
Profitability Inflection And Revenue ExpansionVericel has moved from losses to sustained profitability while expanding revenue from $156.2M in 2021 to $306.3M TTM. Improving operating margins can strengthen reinvestment capacity and make earnings more resilient as the business scales.
Strong Cash Generation And Balance SheetRobust cash conversion and substantial liquidity provide funding for manufacturing expansion, sales-force growth and clinical programs without relying heavily on external capital. Debt-to-equity also improved to approximately 0.27 TTM, supporting financial flexibility.
MACI Adoption And Manufacturing CapacityContinued double-digit MACI growth, record biopsies and implants, and more surgeons using the therapy indicate expanding commercial adoption. Burlington approval adds capacity and supports future geographic expansion, potentially reducing production constraints as demand grows.
Bears Say
Moderating Underlying Revenue GrowthThe sharp slowdown in TTM top-line growth suggests that recent expansion may not be consistently repeatable across periods. Sustaining durable growth will depend on continued MACI surgeon adoption, procedure volumes and successful scaling of Burn Care products.
BARDA Revenue Remains Partly ContingentBARDA could materially expand NexoBrid demand, but much of the headline award depends on future procurement and development decisions. This limits revenue visibility and makes the program’s long-term contribution dependent on government timing and contract execution.
Investment Spending May Pressure MarginsCapacity, commercial and clinical investments may support future growth but create ongoing cost pressure before their benefits fully materialize. The resulting margin variability could constrain near-term earnings conversion and requires sustained revenue growth to achieve targeted profitability.
Vericel News
ATQP FAQ
What was Vericel Corp’s price range in the past 12 months?
Vericel Corp lowest stock price was €25.40 and its highest was €41.60 in the past 12 months.
What is Vericel Corp’s market cap?
Vericel Corp’s market cap is €1.87B.
When is Vericel Corp’s upcoming earnings report date?
Vericel Corp’s upcoming earnings report date is Nov 11, 2026 which is in 75 days.
How were Vericel Corp’s earnings last quarter?
Vericel Corp released its earnings results on Jul 30, 2026. The company reported €0.034 earnings per share for the quarter, beating the consensus estimate of -€0.025 by €0.059.
Is Vericel Corp overvalued?
According to Wall Street analysts Vericel Corp’s price is currently Undervalued.
Does Vericel Corp pay dividends?
Vericel Corp does not currently pay dividends.
What is Vericel Corp’s EPS estimate?
Vericel Corp’s EPS estimate is 0.05.
How many shares outstanding does Vericel Corp have?
Vericel Corp has 51,206,615 shares outstanding.
What happened to Vericel Corp’s price movement after its last earnings report?
Vericel Corp reported an EPS of €0.034 in its last earnings report, beating expectations of -€0.025. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Vericel Corp?
Currently, no hedge funds are holding shares in DE:ATQP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vericel Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€53.76 (37.13% Upside)
€53.76 (37.13% Upside)
Blogger Sentiment
Neutral
DE:ATQP Sentiment 50%
Sector Average 60%
Sector Average 60%
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.41%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
15.44%
Trailing 12-Months
Company Description
Vericel Corp
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.
ATQP Company Deck
ATQP Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive operational and financial quarter: record revenue, double-digit MACI growth, materially improved margins, robust cash generation, successful sales force expansion, regulatory and manufacturing milestones, and a meaningful BARDA award. The key near-term risks are timing and contingent nature of BARDA-related revenue, the need to sustain biopsy-to-implant conversion, modest near-term margin variability due to investments, and external macro/access uncertainties. On balance, the positives substantially outweigh the challenges.View all DE:ATQP earnings summariesATQP Stock 12 Month Forecast
Average Price Target
€53.76
▲(37.13% Upside)